CagriSema contains semaglutide. That makes this comparison unusually clean — the question is not whether two different drugs work, but what the second ingredient adds.
CagriSema pairs semaglutide, the GLP-1 receptor agonist behind Ozempic and Wegovy, with cagrilintide, a long-acting analog of the satiety hormone amylin, in a single once-weekly injection. Because the Phase 3 REDEFINE 1 trial included a semaglutide-alone arm, the two were measured under identical conditions in the same study — a far better comparison than lining up results from separate trials.
At a glance
| CagriSema | Semaglutide | |
|---|---|---|
| Drug class | Amylin analog + GLP-1 agonist (fixed-dose combination) | GLP-1 receptor agonist (single agent) |
| Brand names | None yet — investigational | Ozempic, Wegovy, Rybelsus |
| FDA status | Not approved; under FDA review | Approved for type 2 diabetes, weight management & noncirrhotic MASH |
| Weight loss in REDEFINE 1 (68 weeks) | ~22.7% | ~16.1% (same trial, same protocol) |
| Pathways engaged | Amylin + GLP-1 | GLP-1 only |
| Dosing | Once weekly injection | Once weekly injection; daily oral option |
| Main side effects | Nausea, vomiting, diarrhea, constipation | Nausea, diarrhea, constipation |
| Availability | Clinical trials only | Prescription, widely available |
The bottom line
Bottom line: Adding cagrilintide to semaglutide produced meaningfully more weight loss in the same trial — roughly 22.7% versus 16.1% at 68 weeks. That is a genuine additive effect and it validates the premise that engaging amylin and GLP-1 together beats GLP-1 alone. The practical caveat is availability: semaglutide is approved and prescribable today, while CagriSema remains investigational. It is also worth knowing that in a separate head-to-head, CagriSema did not match tirzepatide — so the relevant benchmark has moved beyond semaglutide.
Frequently asked questions
Is CagriSema stronger than Ozempic?
In the REDEFINE 1 trial, CagriSema produced about 22.7% weight loss at 68 weeks compared with about 16.1% for semaglutide alone in the same study. Ozempic and Wegovy are semaglutide, so on that evidence CagriSema produced more weight loss — but it is not approved or available.
What does cagrilintide add to semaglutide?
Cagrilintide is a long-acting amylin analog. Amylin is a hormone released with insulin that signals fullness through the brainstem, a pathway separate from GLP-1. Adding it engages a second appetite system rather than pushing harder on the same one.
Will CagriSema replace Wegovy?
That depends on approval and on how it is positioned. CagriSema produced more weight loss than semaglutide in trials but did not match tirzepatide in a head-to-head. Wegovy also has established cardiovascular outcome data that a new combination will need years to accumulate.
Are the side effects worse with CagriSema?
Both are dominated by gastrointestinal effects — nausea, vomiting, diarrhea, constipation — and both use gradual dose escalation to limit them. Adding a second appetite-suppressing agent generally adds to the gastrointestinal burden rather than reducing it.
References
Combined peer-reviewed sources from both peptide guides. Inclusion is not endorsement.
- Garvey WT, Blüher M, Osorto Contreras CK, et al. Coadministered Cagrilintide and Semaglutide in Adults with Overweight or Obesity. N Engl J Med. 2025. Peer-reviewed study
- Davies MJ, Bajaj HS, Broholm C, et al. Cagrilintide-Semaglutide in Adults with Overweight or Obesity and Type 2 Diabetes. N Engl J Med. 2025. Peer-reviewed study
- Frias JP, Deenadayalan S, Erichsen L, et al. Efficacy and safety of co-administered once-weekly cagrilintide with once-weekly semaglutide in type 2 diabetes: a phase 2 trial. Lancet. 2023. Peer-reviewed study
- Wilding JPH, Batterham RL, Calanna S, et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1). N Engl J Med. 2021. Peer-reviewed study
- Lincoff AM, Brown-Frandsen K, Colhoun HM, et al. Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes (SELECT). N Engl J Med. 2023. Peer-reviewed study
- Chao AM, Tronieri JS, Amaro A, et al. Semaglutide for the treatment of obesity. Trends Cardiovasc Med. 2023. Peer-reviewed study
- Smits MM, Van Raalte DH. Safety of Semaglutide. Front Endocrinol (Lausanne). 2021. Peer-reviewed study
- Davies M, Færch L, Jeppesen OK, et al. Semaglutide 2·4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial. Lancet. 2021. Peer-reviewed study
- Tan HC, Dampil OA, Marquez MM. Efficacy and Safety of Semaglutide for Weight Loss in Obesity Without Diabetes: A Systematic Review and Meta-Analysis. J ASEAN Fed Endocr Soc. 2022. Peer-reviewed study